Tatva Chintan Pharma Chem LimitedQ1 FY27 Results & Financial Update
Tatva Chintan Pharma Chem Limited: Q1 FY27 consolidated results and company financials – revenue ₹167.06 Cr, PAT ₹15.98 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Tatva Chintan Pharma Chem price & chart
Market price₹1,940.60
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Tatva Chintan Pharma Chem Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Tatva Chintan Pharma Chem Limited reported consolidated revenue from operations of INR 167.055 crore for the quarter ended June 30, 2026, alongside total income of INR 169.835 crore.
Profit before tax before exceptional items stood at INR 22.429 crore, which was affected by an exceptional item charge of INR 1.318 crore, resulting in a reported profit before tax of INR 21.111 crore.
Total tax expenses for the quarter were registered at INR 5.130 crore, comprising current tax of INR 1.010 crore and deferred tax of INR 4.120 crore.
Consolidated net profit after tax for Q1 FY27 stood at INR 15.981 crore, translating to a basic and diluted earnings per share of INR 6.83.
During the quarter, material consumption was reported at INR 105.407 crore, while changes in inventories of finished goods, work-in-progress, and stock-in-trade showed a positive adjustment of INR 31.519 crore.
Employee benefits expense for the period was recorded at INR 16.736 crore, finance costs stood at INR 2.081 crore, and depreciation and amortization expenses reached INR 10.566 crore.
Other expenses were reported at INR 42.732 crore, bringing total consolidated expenses for the quarter to INR 147.406 crore.
01 · Business model
What does Tatva Chintan Pharma Chem do?
Tatva Chintan Pharma Chem Limited operates in the specialty chemicals sector, manufacturing structure-directing agents, phase transfer catalysts, pharmaceutical intermediates, and other specialty chemicals utilized across diverse industrial applications.
The company serves international and domestic markets through manufacturing facilities located in Gujarat, backed by research and development infrastructure designed to support complex chemical synthesis and custom manufacturing mandates.
The operational footprint includes wholly-owned subsidiaries in the United States (Tatva Chintan USA Inc.) and Europe (Tatva Chintan Europe B.V.) that facilitate international distribution and client engagement.
02 · Historical context
What shaped the business before this quarter
Established in 1996 by founding promoters including Mr. Chintan Nitinkumar Shah, Mr. Ajaykumar Mansukhlal Patel, and Mr. Shekhar Rasiklal Somani, the company has expanded its specialty chemical manufacturing capabilities over three decades.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹167.06 Cr |
| Total income | ₹169.84 Cr |
| Profit before tax | ₹21.11 Cr |
| Profit after tax | ₹15.98 Cr |
| EPS | ₹6.83 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 9.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 12.6% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹2.78 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Reported consolidated revenue from operations of INR 167.055 crore for Q1 FY27, supported by total income of INR 169.835 crore including other income of INR 2.780 crore.
What drove margins
Cost of materials consumed stood at INR 105.407 crore, offset by inventory adjustments of INR 31.519 crore, while employee benefits and other expenses amounted to INR 16.736 crore and INR 42.732 crore respectively.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company maintains only one reportable business segment, namely specialty chemicals, pursuant to Ind AS 108 operating segment disclosures.
Geography and market mix
Global operations are supported through wholly-owned overseas entities including Tatva Chintan USA Inc. and Tatva Chintan Europe B.V.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The Board approved a proposed capacity addition involving the installation of an aggregate reactor capacity of 344 kilolitres (KL) at a new greenfield unit located at Dahej - III, GIDC Industrial Estate, Bharuch, Gujarat.
Projects, capex and execution
The estimated capital expenditure for the Dahej-III expansion is approximately INR 200 crore, scheduled for completion within approximately 21 months, financed through a combination of internal accruals and debt.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The Board approved the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director, Mr. Ajaykumar Mansukhlal Patel as Whole-time Director, and Mr. Shekhar Rasiklal Somani as Whole-time Director for a further three-year term effective February 1, 2027.
08 · Reported developments
What changed operationally
Statutory auditors NDJ & Co. issued an unmodified limited review report on both the consolidated and standalone financial results for Q1 FY27.
09 · Pressure points & risks
What is not going smoothly
The quarter's financial results include an exceptional item charge of INR 1.318 crore affecting pre-tax profitability.
10 · Items worth noticing
The line items that can distort a quick read
Recognition of an exceptional item amounting to INR 13.18 million (INR 1.318 crore) during the quarter ended June 30, 2026.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The Board approved an increase in the company's borrowing limits under Section 180(1)(c) of the Companies Act, 2013, from INR 300 crore to INR 1,000 crore, subject to shareholder approval at the ensuing Annual General Meeting.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Executive Re-appointments
The Nomination and Remuneration Committee recommended and the Board approved executive re-appointments for key managerial personnel holding founding roles since 1996.
13 · Key Q&A
The quarter, answered directly
What does Tatva Chintan Pharma Chem do?
Tatva Chintan Pharma Chem Limited operates in the specialty chemicals sector, manufacturing structure-directing agents, phase transfer catalysts, pharmaceutical intermediates, and other specialty chemicals utilized across diverse industrial applications.
What is the clearest takeaway from Q1 FY27?
Tatva Chintan Pharma Chem Limited reported consolidated revenue from operations of INR 167.055 crore for the quarter ended June 30, 2026, alongside total income of INR 169.835 crore.
What drove revenue or demand?
Reported consolidated revenue from operations of INR 167.055 crore for Q1 FY27, supported by total income of INR 169.835 crore including other income of INR 2.780 crore.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 105.407 crore, offset by inventory adjustments of INR 31.519 crore, while employee benefits and other expenses amounted to INR 16.736 crore and INR 42.732 crore respectively.
What changed operationally beyond the headline numbers?
The Board approved a proposed capacity addition involving the installation of an aggregate reactor capacity of 344 kilolitres (KL) at a new greenfield unit located at Dahej - III, GIDC Industrial Estate, Bharuch, Gujarat.
What are the main pressure points disclosed for the quarter?
The quarter's financial results include an exceptional item charge of INR 1.318 crore affecting pre-tax profitability.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Dahej-III Project Execution: Monitor the progress and capital deployment for the 344 KL reactor capacity expansion at the Dahej-III greenfield facility over the projected 21-month timeline.
- 02
Shareholder Approvals: Track upcoming shareholder approvals at the annual general meeting regarding the enhanced borrowing limits of up to INR 1,000 crore and executive re-appointments.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.